BR100 Decreased By (-0.73%)
BR30 Decreased By (-0.77%)
KSE100 Decreased By (-0.49%)
KSE30 Decreased By (-0.47%)
BECO 5.77 Increased By ▲ 0.46 (8.66%)
BML 53.00 Increased By ▲ 1.42 (2.75%)
BOP 33.99 Increased By ▲ 0.03 (0.09%)
CNERGY 8.11 Decreased By ▼ -0.20 (-2.41%)
DCL 12.20 Increased By ▲ 0.40 (3.39%)
FCCL 52.83 Decreased By ▼ -0.17 (-0.32%)
FCSC 5.07 Increased By ▲ 0.12 (2.42%)
FFL 17.95 Decreased By ▼ -0.20 (-1.1%)
FNEL 1.29 Decreased By ▼ -0.03 (-2.27%)
HUMNL 10.88 Decreased By ▼ -0.12 (-1.09%)
KEL 8.02 Decreased By ▼ -0.12 (-1.47%)
KOSM 5.52 Decreased By ▼ -0.06 (-1.08%)
MLCF 86.51 Decreased By ▼ -1.37 (-1.56%)
NBP 185.16 Decreased By ▼ -2.53 (-1.35%)
PACE 10.58 Decreased By ▼ -0.23 (-2.13%)
PAEL 39.42 Decreased By ▼ -0.65 (-1.62%)
PIAHCLA 26.22 Decreased By ▼ -0.27 (-1.02%)
PIBTL 16.67 Decreased By ▼ -0.09 (-0.54%)
PPL 228.18 Decreased By ▼ -2.19 (-0.95%)
PRL 34.68 Decreased By ▼ -0.36 (-1.03%)
PTC 65.33 Increased By ▲ 0.82 (1.27%)
SEARL 90.13 Increased By ▲ 0.25 (0.28%)
SSGC 26.60 Decreased By ▼ -0.37 (-1.37%)
TELE 8.28 Decreased By ▼ -0.09 (-1.08%)
THCCL 58.50 Decreased By ▼ -0.58 (-0.98%)
TPLP 8.22 Increased By ▲ 0.04 (0.49%)
TREET 24.53 Decreased By ▼ -0.47 (-1.88%)
TRG 69.71 Decreased By ▼ -0.92 (-1.3%)
WAVES 9.94 Decreased By ▼ -0.07 (-0.7%)
WTL 1.28 Decreased By ▼ -0.01 (-0.78%)
Topic

research

COVID-19 caused $220 billion of global dividend cuts in 2020: Research

COVID-19 caused $220 billion of global dividend cuts in 2020: Research

Updated 22 Feb, 2021 03:42pm
  • According to research, the coronavirus pandemic led to a sharp decline in global dividends last year, with the amount of investor payouts declining by 12.6% to $1.26 trillion.
  • As the public health crisis impacted every corner of the globe, prompting lockdowns and inhibiting economic activity, dividend cuts amounted to $220 billion, according to the Global Dividend Index.
Britain trial to test combining Pfizer and AstraZeneca vaccines in two-shot regimen

Britain trial to test combining Pfizer and AstraZeneca vaccines in two-shot regimen

Published 04 Feb, 2021 03:14pm
  • The British researchers behind the trial say data on vaccinating people with the two different types of coronavirus vaccines could help understanding of whether shots can be rolled out with greater flexibility around the world
  • The trial will examine the immune responses of an initial dose of Pfizer vaccine followed by a booster of AstraZeneca vaccine
Twitter grants academics full access to public data, but not for suspended accounts

Twitter grants academics full access to public data, but not for suspended accounts

Published 27 Jan, 2021 10:09am
  • Twitter Inc on Tuesday opened free access to its new application programming interface (API) software for academic researchers, enabling them to study public conversations on its platform.
  • Twitter said, with the new product, academic researchers will be able to tap into all the tools released to date on the new API platform, which will enable them to listen to and analyze public conversations.
£100m donated to Oxford University for antibiotic resistance research

£100m donated to Oxford University for antibiotic resistance research

Published 19 Jan, 2021 07:11pm
  • On Tuesday, Oxford University received a donation of £100 million ($136 million) to research growing resistance to antibiotics.
  • The donation, contributed by British multinational chemicals production company Ineos, is one of the largest donations given to Oxford University in its long history.
Indus Hospital denies Global Fund allegations of misappropriation of funds

Indus Hospital denies Global Fund allegations of misappropriation of funds

Updated 16 Jan, 2021 03:41pm
  • Dr. Abdul Bari Khan, the Chief Executive Officer at the Indus Hospital, rejected all such reports, terming them "misleading, exaggerated and not based on facts".
  • Yesterday, The Global Fund, international financing and partnership organization, claimed that Indus hospital had committed a $4.2 million procurement fraud from a grant that was meant to eradicate tuberculosis (TB).
Loading...